mounjaro retatrutide vs Tirzepatide: 28.7% vs 22.5% (2026) Mounjaro vs retatrutide

Because retatrutide includes GLP-1 agonism (which semaglutide was providing) plus GIP and glucagon agonism, the transition should not result in loss of appetite suppression during the switch

Keep each peptide in its own vial, draw with its own syringe, and inject at separate sites

90.Desalermos A, Russell B, Leggett C, et al

The major players in the obesity GLP-1 market include Novo Nordisk A/S, Eli Lilly and Company, Amgen, Viking Therapeutic, AstraZeneca, Roche (Carmot Therapeutics), Boehringer Ingelheim, Pfizer Inc., Altimmune, Inc., and Structure Therapeutics

Evidence of beta-cell dedifferentiation in human type 2 diabetes